Most Read Articles
01 Apr 2016
Posaconazole oral suspension may be effective in managing fungal infections among lung transplant recipients, as presented in a single-centre, retrospective study.
Saras Ramiya, 19 Nov 2018
Sunway Medical Centre is collaborating with Royal Papworth Hospital to facilitate knowledge exchange among cardiology and respiratory experts.
Tristan Manalac, 11 Sep 2018
The immediate reduction of cigarette nicotine content results in greater improvements in levels of smoke exposure biomarkers than gradual reduction, though withdrawal symptoms are stronger, according to a recent study.
Stephen Padilla, 6 days ago
Happy Quit, a mobile-phone-based text messaging intervention, has led smokers in a China study to stop smoking with either high- (HFM) or low-frequency messaging (LFM). This intervention may be paired with other smoking cessation services for treatment-seeking smokers.

Indacaterol/glycopyrronium use tied to lower exacerbation risk in patients with COPD

Elaine Soliven
09 Dec 2017

The use of indacaterol/glycopyrronium (IND/GLY) may reduce exacerbation risk in patients with chronic obstructive pulmonary disease (COPD), according to the DACCORD* study presented at APSR 2017.

This study evaluated 467 patients (mean age 67.1 years, 56.7 percent male) with COPD. Participants were switched from LABA + ICS (long-acting β2-agonist + inhaled corticosteroid) to IND/GLY therapy regimen. COPD assessment test (CAT) results were collected. Patients were followed up every 3 months for a year. [APSR 2017, abstract AP235]

A higher percentage of patients had no COPD exacerbation with IND/GLY treatment at 1-year follow-up compared with baseline (77.9 percent vs 68.5 percent).

Also, the percentage of patients who had one or more exacerbations was reduced with IND/GLY at 1-year follow-up compared with baseline (15.8 percent vs 31 percent).

Based on the CAT total score, majority of the participants who were switched from LABA + ICS to IND/GLY treatment reported a reduction in the CAT total score from 20.7 percent at baseline to 17.4 percent at 1-year follow-up.

In addition, a 1-year treatment persistence rate was noted to be higher with IND/GLY vs LABA + ICS treatment (86.7 percent vs 4.7 percent).

“Majority of patients [experienced] a clinically relevant improvement in health status [with IND/GLY treatment],” said lead author Prof Konstantinos Kostikas from the Division of Respiratory Diseases II at National and Kapodistrian University of Athens, Athens, Greece.

The findings were consistent with a previous study which revealed that indacaterol treatment was associated with an increased physical activity in patients with moderate COPD. [BMC Pulm Med 2014;14:158]

“This real-life study supports the new GOLD** recommendations, suggesting that [a] switch from LABA + ICS to [IND/GLY] is a valid treatment option for patients with COPD in clinical practice,” Kostikas noted.

 

*DACCORD: Outpatient care with long-acting bronchodilators

**GOLD: Global Initiative for Chronic Obstructive Lung Disease
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Apr 2016
Posaconazole oral suspension may be effective in managing fungal infections among lung transplant recipients, as presented in a single-centre, retrospective study.
Saras Ramiya, 19 Nov 2018
Sunway Medical Centre is collaborating with Royal Papworth Hospital to facilitate knowledge exchange among cardiology and respiratory experts.
Tristan Manalac, 11 Sep 2018
The immediate reduction of cigarette nicotine content results in greater improvements in levels of smoke exposure biomarkers than gradual reduction, though withdrawal symptoms are stronger, according to a recent study.
Stephen Padilla, 6 days ago
Happy Quit, a mobile-phone-based text messaging intervention, has led smokers in a China study to stop smoking with either high- (HFM) or low-frequency messaging (LFM). This intervention may be paired with other smoking cessation services for treatment-seeking smokers.